



## UvA-DARE (Digital Academic Repository)

### Oral contraceptives and the risk of venous thrombosis

Vandenbroucke, J.P.; Rosing, J.; Bloemenkamp, K.W.M.; Middeldorp, S.; Helmerhorst, F.M.; Bouma, B.N.; Rosendaal, F.R.

**DOI**

[10.1056/NEJM200105173442007](https://doi.org/10.1056/NEJM200105173442007)

**Publication date**

2001

**Published in**

The New England journal of medicine

[Link to publication](#)

**Citation for published version (APA):**

Vandenbroucke, J. P., Rosing, J., Bloemenkamp, K. W. M., Middeldorp, S., Helmerhorst, F. M., Bouma, B. N., & Rosendaal, F. R. (2001). Oral contraceptives and the risk of venous thrombosis. *The New England journal of medicine*, 344(20), 1527-1535.  
<https://doi.org/10.1056/NEJM200105173442007>

**General rights**

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

**Disclaimer/Complaints regulations**

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: <https://uba.uva.nl/en/contact>, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

## Review Article

*Medical Progress***ORAL CONTRACEPTIVES AND THE RISK OF VENOUS THROMBOSIS**

JAN P. VANDENBROUCKE, M.D., PH.D., JAN ROSING, PH.D.,  
 KITTY W.M. BLOEMENKAMP, M.D., PH.D.,  
 SASKIA MIDDELDORP, M.D., PH.D.,  
 FRANS M. HELMERHORST, M.D., PH.D.,  
 BONNO N. BOUMA, PH.D.,  
 AND FRITS R. ROSENDAAL, M.D., PH.D.

**I**N the early 1960s, shortly after the introduction of oral contraceptives, the first case reports appeared describing venous thrombosis and pulmonary emboli in women using this method of birth control. Later, myocardial infarction and stroke were also found to be associated with the use of oral contraceptives. These observations led to numerous epidemiologic and clinical studies of oral-contraceptive pills and thrombosis and subsequently to the development of new oral contraceptives with a lower estrogen content. These lower-estrogen contraceptives were considered safer: changes in hemostatic factors remained small, inconsistent in direction, and mostly within the normal range.<sup>1-4</sup>

Recent studies have challenged the concept that reducing the dose of estrogen in oral contraceptives eliminates the risk of venous thrombosis. These studies have included epidemiologic data suggesting that certain progestins may increase the risk of thrombosis associated with low-estrogen preparations, new findings regarding individual genetic susceptibilities to the thrombogenic effect of oral contraceptives, and new insights into the hemostatic changes that predispose women to thrombosis. These advances have consequences with respect to the development of new contraceptives and tailoring of the prescription of currently available preparations.

From the Department of Clinical Epidemiology (J.P.V., F.R.R.), the Department of Obstetrics, Gynecology, and Reproductive Medicine (K.W.M.B., F.M.H.), and the Thrombosis and Haemostasis Research Center (F.R.R.), Leiden University Medical Center, Leiden; the Department of Biochemistry, Cardiovascular Research Institute, Maastricht (J.R.); the Department of Vascular Medicine, Academic Medical Center, Amsterdam (S.M.); and the Thrombosis and Hemostasis Laboratory, Department of Hematology, University Hospital Utrecht, Utrecht (B.N.B.) — all in the Netherlands. Address reprint requests to Dr. Vandenbroucke at the Department of Clinical Epidemiology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, the Netherlands, or at vdbroucke@mail.medfac.leidenuniv.nl.

Arterial thrombosis is also a complication of oral-contraceptive therapy, but the risk factors for this condition differ from those for venous thrombosis. For example, smoking increases the risk of myocardial infarction associated with the use of oral contraceptives,<sup>5,6</sup> but it has no material effect on the risk of venous thrombosis in users of oral contraceptives.<sup>7,8</sup> In contrast, several prothrombotic genetic defects are strong risk factors for venous thrombosis and increase the risk associated with the use of oral contraceptives, but most are likely to be only weak risk factors for myocardial infarction or stroke. This review will focus on recent developments in our understanding of venous thrombosis as a side effect of oral-contraceptive use.

**RISKS ASSOCIATED WITH LOW-DOSE ORAL CONTRACEPTIVES**

In 1981, Stadel estimated that the risk of venous thrombosis was increased by a factor of four in users of oral contraceptives.<sup>9</sup> This estimate reflected the use of the oral contraceptives available in the 1970s, which were predominantly “high-dose” (estrogen content, 50  $\mu$ g or more of ethinylestradiol). At that time, little was known about the effect of lowering the dose of ethinylestradiol below 50  $\mu$ g.

Primarily on the basis of studies involving the use of “low-dose” oral contraceptives (30 to 40  $\mu$ g of ethinylestradiol), an expert committee of the World Health Organization concluded in 1998 that current users of oral contraceptives have a risk of venous thrombosis that is three to six times that of non-users.<sup>10</sup> The highest risk occurred during the first year of use, and an increased risk persisted until, but not beyond, the discontinuation of the contraceptives. A recent review of studies involving healthy young women without risk factors<sup>11</sup> also reported that the risk of venous thrombosis increased by a factor of 3 to 6; one study estimated an increase in risk by a factor of 11 (Table 1).<sup>12-16</sup> The absolute risk, however, remains low. A base-line risk of less than 1 per 10,000 person-years is increased to 3 to 4 per 10,000 person-years during the time when oral contraceptives are being used.<sup>6,8,11</sup>

One issue of concern regarding the methods used in studies of the risk of venous thrombosis with oral contraceptives is the possibility of diagnostic-suspicion and referral bias. In other words, the awareness by the physician that a patient with calf pain or swelling is taking oral contraceptives might increase the likelihood that the patient will be evaluated for deep-vein thrombosis<sup>17</sup> and might lead to an overestimation of the risk posed by oral contraceptives. The finding in early studies that the risks associated with oral con-

**TABLE 1.** CURRENT BEST EVIDENCE OF THE RISK OF VENOUS THROMBOSIS AMONG APPARENTLY HEALTHY USERS OF AVAILABLE LOW-DOSE COMBINED ORAL CONTRACEPTIVES.\*

STUDY	YEARS INCLUDED	AGE RANGE	STUDY DESIGN	EVENTS	NO. IN WHOM VENOUS THROMBOSIS DEVELOPED	RELATIVE RISK (95% CI)
		yr				
Helmrich et al. <sup>12</sup>	1976–1983	18–49	Case–control	Nonfatal deep venous thromboembolism and pulmonary embolism	5	11.0 (3.7–32.0)
Vessey et al. <sup>13</sup>	1968–1985	25–56	Cohort	Fatal and nonfatal superficial venous thrombophlebitis, deep venous thromboembolism, and pulmonary embolism	3	3.3 (0.9–11.4)
World Health Organization <sup>14</sup>	1989–1993	15–49	Case–control	Nonfatal deep venous thromboembolism and pulmonary embolism	132 from Europe, <35 yr old 42 from Europe, ≥35 yr old 93 from developing country, <35 yr old 28 from developing country, ≥35 yr old	4.3 (2.9–6.5) 3.9 (2.3–6.6) 3.2 (2.3–4.5) 2.5 (1.5–4.3)
Jick et al. <sup>15</sup>	1991–1994	<40	Cohort	Nonfatal deep venous thromboembolism and pulmonary embolism	75	6.1 (2.5–15.1)
Lewis et al. <sup>16</sup>	1993–1995	16–44	Case–control	Fatal and nonfatal deep venous thromboembolism and pulmonary embolism	334	4.4 (3.4–5.8)

\*Adapted from Hannaford and Owen-Smith.<sup>11</sup> CI denotes confidence interval.

traceptives were similar regardless of whether the diagnosis of venous thrombosis was certain or uncertain suggested that such a bias was not the explanation for the observed risks.<sup>18,19</sup>

More recently, two studies addressed this issue by focusing on women who were referred to testing facilities for clinically suspected deep-vein thrombosis.<sup>20,21</sup> A case was defined as an objectively confirmed diagnosis of venous thrombosis, and controls were women with similar cause for clinical suspicion who proved not to have venous thrombosis. Information about the use of oral contraceptives was obtained before diagnostic testing was conducted. The relative risk of confirmed venous thrombosis associated with oral contraceptives was 6.4 (95 percent confidence interval, 1.2 to 34.3) in the smaller study<sup>20</sup> and 3.9 (95 percent confidence interval, 2.6 to 5.7) in the larger study.<sup>21</sup> These results confirm the existence of an increased risk associated with the use of modern oral contraceptives that cannot be explained by surveillance bias.

#### THE EFFECT OF PROGESTINS IN COMBINED PREPARATIONS

Before 1995, the progestin component of oral contraceptives was not generally thought to contribute to the risk of thrombosis. However, more recent data showing a higher risk of venous thrombosis with third-generation progestins (desogestrel and gestodene) than with second-generation progestins (e.g., levonorgestrel and norgestrel) have challenged this view.<sup>15,22–24</sup> Whereas the beneficial effects of third-generation progestins on the levels of high-density lipoprotein cholesterol had suggested that they might

lower the risk of arterial thrombosis, studies demonstrated a relative risk of venous thrombosis in users of these oral contraceptives that was six to nine times that in nonusers.<sup>22–24</sup>

Of 16 original studies addressing the risk of third-generation as compared with second-generation oral contraceptives, 3 found no difference between the two types of contraceptives<sup>25–27</sup> and all the others found higher risks associated with the use of third-generation preparations, with estimates of risk ranging from 1.4 to 4 times as high as that associated with second-generation preparations.<sup>15,21–24,28–35</sup> In a prospective study involving a pharmacy data base in the Netherlands, the absolute risk associated with third-generation contraceptives approached 1 per 1000 new users per year during the first year of use.<sup>32</sup> This finding is consistent with those of earlier studies that also found higher risks among first-time users.<sup>15,22,23,36</sup>

Findings of an increased risk with third-generation contraceptives led to a protracted debate about possible bias and confounding.<sup>6,16,37–47</sup> Some suggested that oral contraceptives were being differentially prescribed on the basis of the patient's underlying risk factors,<sup>41</sup> but the appropriate stratification for risk factors such as obesity and age did not eliminate the difference in risk between third-generation and second-generation contraceptives.<sup>6,46</sup> The possibility that the findings were due to selective "attrition of susceptibles"<sup>16,41</sup> was addressed by the confirmation of the findings in a separate analysis of the first year of use.<sup>6,36,46</sup> Reanalyses according to the duration of use were suggested,<sup>41–43</sup> but they failed to reverse the findings convincingly.<sup>6,40,46</sup> Taking into account these and other methodologic considerations, independent ex-

perts who were not involved in the original studies concluded that bias and confounding could not explain the consistent epidemiologic findings of an increased risk.<sup>10,44-48</sup> Recent package inserts for third-generation oral contraceptives used in the United States and the United Kingdom explain that they are associated with a higher risk of venous thrombosis than are other oral contraceptives.

The epidemiologic evidence that some oral contraceptives are more thrombogenic than others led to the elucidation of the hemostatic mechanisms that may underlie the association between oral contraceptives and venous thrombosis.

### SUSCEPTIBILITY TO PROTHROMBOTIC STATES

#### Hereditary Resistance to Activated Protein C and the Factor V Leiden Mutation

In 1993, Dahlbäck et al. described a newly recognized hereditary prothrombotic condition<sup>49</sup>: the diminished anticoagulant response, or resistance, to activated protein C. The activated protein C system is one of the hemostatic checks and balances that inhibit coagulation. Dahlbäck et al. described persons from families with multiple episodes of venous thrombosis who had normal levels of protein C, but in whom activated protein C did not have its expected anticoagulant effect. One year later, the molecular basis was identified as a mutation in coagulation factor V (the substitution of adenine for guanine at nucleotide 1691) at one of the sites where activated protein C exerts its inactivating effect by cleaving factor V.<sup>50</sup> The mutant factor is commonly referred to as factor V Leiden. Its prevalence is about 5 percent in white persons, with some geographic variation, but it is virtually absent in Asian and African populations.<sup>51,52</sup> The presence of factor V Leiden increases the risk of venous thrombosis by a factor of 4 to 10 in heterozygotes and by a factor of 50 to 100 in homozygotes.<sup>53</sup>

It is now recognized that factor V Leiden greatly increases the risk of venous thrombosis associated with oral-contraceptive use (Fig. 1).<sup>8</sup> As compared with the base-line risk for women who do not use oral contraceptives and do not carry factor V Leiden, the risk is increased by a factor of 4 in those who use oral contraceptives but do not carry factor V Leiden, by a factor of 7 in carriers of the factor V mutation who do not use oral contraceptives, and by a factor of 35 in women who carry the mutation and also use oral contraceptives. This susceptibility has been confirmed in other studies<sup>29,54</sup> and is even higher in the few women who are homozygous for this mutation.<sup>53</sup>

#### Other Hereditary Prothrombotic Defects

The prevalence of previously recognized prothrombotic defects — deficiencies of protein C, protein S, and antithrombin — is much lower than that of fac-

tor V Leiden; their combined prevalence is less than 1 to 2 percent.<sup>55,56</sup> Their rarity makes it difficult to conduct extensive studies of the interaction between these defects and the use of oral contraceptives. Nevertheless, multiple case reports and studies in large families indicate that the risk is particularly high in young women with these defects who begin to use oral contraceptives.<sup>57-59</sup> Another recently identified genetic defect, a mutation in the prothrombin gene (the substitution of adenine for guanine at nucleotide 20210), is a moderate risk factor for thrombosis; its prevalence among white persons is approximately 2 to 4 percent,<sup>60,61</sup> and it has also been shown to increase the risk of venous thrombosis associated with the use of oral contraceptives.<sup>27</sup>

Women who have a prothrombotic defect have oral-contraceptive-associated venous thrombosis not only more often, but also sooner: their risk of venous thrombosis in the first year of use is more than 10 times that in later years.<sup>62</sup> Thus, the development of venous thrombosis in the first year of use may be a warning that a woman has a hereditary risk factor for venous thrombosis.<sup>62</sup>

#### Prothrombotic Conditions of Uncertain Heredity


High levels of factor VIII are linked to blood groups other than O,<sup>63,64</sup> which accounts in part for the observation that having a blood group other than O increases the risk of venous thrombosis by a factor of about 1.6 in general, and by a factor of 3.3 among users of oral contraceptives.<sup>65</sup> However, some data have suggested that the effects of high levels of factor VIII and the use of oral contraceptives are merely additive.<sup>66</sup>

A recent study of carriers of factor V Leiden demonstrated that women with blood groups other than O were four times as likely to have venous thrombosis than those with blood group O. This increased risk was greater than previous general estimates derived from studies in unselected patients and points to a possible interaction.<sup>67</sup>

### MECHANISMS OF VENOUS THROMBOSIS INDUCED BY ORAL CONTRACEPTIVES

Until recently, it was uncertain whether the use of low-dose oral contraceptives disturbed the hemostatic balance.<sup>1-4</sup> Potential prothrombotic effects included increases in the levels of coagulant factors and decreases in the levels of the anticoagulant proteins antithrombin and protein S. However, these changes were believed to be at least partially counterbalanced by such antithrombotic effects as increases in the levels of other anticoagulant proteins and increased fibrinolysis. Furthermore, the levels of coagulation factors typically remained within the normal range during oral-contraceptive use.<sup>1-4</sup>

New studies of the effects of second-generation and third-generation oral contraceptives on the pro-



**Figure 1.** Cases of Deep-Vein Thrombosis per 10,000 Person-Years, According to the Use of Oral Contraceptives and the Presence of Factor V Leiden.

coagulant, anticoagulant, and fibrinolytic pathways, in contrast, indicate that oral contraceptives have a net prothrombotic effect. Quantitatively, the effect is greater with preparations that confer a higher risk of thrombosis. The hemostatic factors involved in this process are shown in Figure 2.<sup>68</sup>

#### Procoagulant Effects

A recent randomized, crossover study<sup>69</sup> confirmed that there are increases in the levels of prothrombin, factor VII, factor VIII, factor X, fibrinogen, and prothrombin fragment 1+2 and decreases in the levels of factor V during the use of oral contraceptives. The increase in prothrombin and factor VII and the decrease in factor V were significantly more pronounced with the use of third-generation oral contraceptives (those containing desogestrel) than with the use of second-generation oral contraceptives containing levonorgestrel. It is now recognized that moderately increased levels of prothrombin<sup>60</sup> and factor VIII<sup>63,64</sup> are associated with an increased risk of venous thrombosis. Since factor V may exhibit anticoagulant activity because of its ability to act as a cofactor in the inactivation of activated factor VIII that is mediated by activated protein C,<sup>70,71</sup> a decrease in the level of factor V may contribute to the thrombotic side effects of oral contraceptives.


#### Anticoagulant Effects

Oral contraceptives have profound effects on the anticoagulant system. Between 1994 and 1997 there

were several reports that acquired resistance to activated protein C develops in women who use oral contraceptives. Like carriers of factor V Leiden (who have hereditary resistance to activated protein C), these women become less sensitive to the anticoagulant action of activated protein C.<sup>72-76</sup> Furthermore, third-generation oral contraceptives cause more pronounced resistance than do second-generation oral contraceptives.<sup>76-78</sup> The clinical relevance of acquired resistance to activated protein C during the use of oral contraceptives is evidenced by the observation that the levels of resistance reported among users of oral contraceptives, carriers of factor V Leiden, and heterozygous carriers of factor V Leiden who use oral contraceptives correlate with the relative risks of venous thrombosis that have been found in epidemiologic studies to be associated with these conditions.<sup>76-79</sup> Since resistance to activated protein C, even in the absence of factor V Leiden, is an independent risk factor for venous thrombosis,<sup>80,81</sup> these observations support the theory that acquired resistance to activated protein C contributes to the increased risk of thrombosis in users of oral contraceptives. The molecular basis of acquired resistance to activated protein C during the use of oral contraceptives is unknown. Decreased levels of plasma protein S, the cofactor of activated protein C (the levels of which were significantly lower in users of desogestrel<sup>82</sup>), only partially explain the resistance to activated protein C found in users of oral contraceptives.

#### Fibrinolytic Effects

Changes in fibrinolytic variables (plasminogen, tissue plasminogen activator, plasminogen-activator inhibitor type 1, and plasmin-antiplasmin complexes) with the use of oral contraceptives suggest that fibrinolytic activity is increased.<sup>1-4,83</sup> It is not known whether enhanced fibrinolytic activity during oral-contraceptive use has clinical implications, since changes in the fibrinolytic system have not been demonstrated to affect the risk of venous thrombosis. One antifibrinolytic mechanism involves thrombin-activatable fibrinolysis inhibitor (TAFI), which, when activated, inhibits fibrinolysis by removing from fibrin the lysine residues that are essential for the binding and activation of plasminogen.<sup>84,85</sup> Elevated levels of TAFI are a risk factor for venous thrombosis.<sup>86</sup> An assay for clot lysis that probes the activity of both the fibrinolytic system and the TAFI-dependent antifibrinolytic pathway demonstrated that the overall clot-lysis time remained unchanged during oral-contraceptive use.<sup>83</sup> This finding suggests that in the users of oral contraceptives an enhanced down-regulation of fibrinolysis by the TAFI system compensates for the increased fibrinolytic potential. Levels of TAFI are higher in women taking contraceptives containing desogestrel than in those taking contraceptives containing levonorgestrel, indicating a stronger down-regulation of



**Figure 2.** Regulation of Blood Coagulation and Fibrinolysis.

Coagulation is initiated by a tissue factor (TF)–factor VIIa complex that can activate factor IX or factor X. At high tissue factor concentrations, factor X is activated primarily by the TF–VIIa complex, whereas at low tissue factor concentrations the contribution of the factor IXa–factor VIIIa complex to the activation of factor X becomes more pronounced. Tissue factor–dependent coagulation is rapidly inhibited by tissue factor–pathway inhibitor (TFPI). Coagulation is maintained through the activation by thrombin of factor XI. Through the intrinsic tenase complex (factors IXa and VIIIa) and the prothrombinase complex (factors Xa and Va), the additional thrombin required to down-regulate fibrinolysis is generated by the activation of thrombin-activatable fibrinolysis inhibitor (TAFI). Activated TAFI down-regulates fibrinolysis by removing from partially degraded fibrin C-terminal lysine residues that are involved in the binding and activation of plasminogen. The coagulation system is regulated by the protein C pathway. Thrombin activates protein C in the presence of thrombomodulin. Together with protein S, activated protein C (APC) is capable of inactivating factors Va and VIIIa, which results in a down-regulation of thrombin generation and consequently in an up-regulation of the fibrinolytic system. The activity of thrombin is controlled by the inhibitor antithrombin. The solid arrows indicate activation and the broken arrows inhibition. To improve the clarity of the figure, most zymogens and procoagulant surfaces are not depicted. Modified from Bouma et al.<sup>68</sup> with the permission of the publisher.

fibrinolysis with the former type of contraceptive.<sup>83</sup> The increased TAFI-dependent inhibition of fibrinolysis most likely results from both elevated levels of TAFI and enhanced formation of thrombin (the activator of TAFI).

#### Overall Hemostatic Effect

The increase in procoagulant effects, the decrease in anticoagulant effects, and the equivocal effects on fibrinolysis (with increases in the activity of the antifibrinolytic system) indicate that oral contraceptives have a net prothrombotic effect. Significant differences between users of oral contraceptives that contain levonorgestrel and users of those that contain desogestrel in the plasma levels of prothrombin, fac-

tor V, factor VII, and protein S and in susceptibility to the anticoagulant action of activated protein C may explain the higher risk of venous thrombosis observed in users of third-generation oral contraceptives. The more pronounced hemostatic changes associated with third-generation oral contraceptives might be related to their increased estrogenic profile, which might also cause the moderate increase in the level of high-density lipoprotein cholesterol that has been observed in women using these contraceptives.<sup>87</sup>

#### CONCLUSIONS

Hormonal contraception is used by more than 100 million women worldwide.<sup>10</sup> The number of excess deaths from cardiovascular disease (venous and

arterial combined) among young, low-risk users — nonsmoking women between 20 and 24 years of age — ranges from 2 to 6 per million per year worldwide,<sup>88</sup> depending on the region of the world, the underlying cardiovascular risk, and the extent of the screening for risk factors that is performed before the contraceptives are prescribed. Whereas the risk of venous thrombosis is more important for younger users, the risk of arterial thrombosis becomes more important at older ages. Among older smokers who use oral contraceptives, the number of excess deaths is estimated to vary from 100 to slightly more than 200 per million per year.<sup>88</sup>

The reduction of the dose of estrogen has had a limited effect on reducing the risk of venous thrombosis. Third-generation progestins in combination preparations increase the extent of adverse hemostatic changes and the associated risk of thrombosis and thus should not be the first choice for new users.<sup>34,39,40,47</sup> The ability to prescribe prudently by withholding oral contraceptives from women with known risk factors is limited by the absence, in the majority of cases, of clinically recognizable risk factors for venous thrombosis. An investigation in New Zealand of a series of deaths due to pulmonary emboli suggested that in most cases physicians could not have foreseen the risk.<sup>89</sup>

In contrast, prudent prescribing can help prevent arterial thrombosis; almost all women who have a myocardial infarction during the use of oral contraceptives are older and either smoke or have other risk factors for arterial disease — in particular, hypertension.<sup>5</sup> The avoidance of the use of oral contraceptives by such women may underlie the reduction in the rates of arterial thrombosis reported in recent studies in industrialized countries.<sup>5,6,88</sup> The beneficial effect that third-generation contraceptives theoretically have on the lipid profile has not translated into a lower incidence of stroke or myocardial infarction in large case-control studies.<sup>90,91</sup>

To prevent venous thrombosis when prescribing oral contraceptives, physicians generally consider a personal history of venous thrombosis to be an absolute contraindication, although little is known about the risk of recurrence during the use of oral contraceptives. The only existing evidence is indirect; venous thrombotic disease that occurred during the use of oral contraceptives was less likely to recur when the contraceptives were stopped.<sup>92</sup> Contraceptives containing low doses of progestin alone (first-generation or second-generation) are associated with a lower risk of venous thrombosis than are combined preparations<sup>33,93</sup>; however, the risk among women with a history of thrombosis is unknown.

Gross obesity is a recognized risk factor for venous thrombosis, but it is unknown whether it increases the risk associated with the use of oral contraceptives, and thrombosis is rare even among obese users. Obes-

ity is therefore not considered a contraindication to the use of oral contraceptives. Superficial varicose veins that are not the consequence of a previous venous thrombosis are not, by themselves, risk factors for deep venous thrombosis.<sup>94</sup> A family history of venous thrombosis may cause concern, although the sensitivity of a family history as a marker for identifying persons at high risk remains unclear. A personal history of superficial thrombophlebitis might also suggest a hereditary risk factor, especially if it is coupled with a family history of the disorder.

The susceptibility to venous thrombosis conferred by factor V Leiden and other prothrombotic mutations has led to questions about the value of screening for these mutations before oral contraceptives are prescribed. In the absence of a clear family history of venous thrombosis, there is little justification to screen for prothrombotic mutations. More than half a million women would need to be screened for factor V Leiden to avoid a single death from pulmonary embolus, since only 5 percent of women are carriers and the mortality associated with venous thrombosis in young women is low.<sup>95</sup> If all the costs associated with the treatment of all occurrences of venous thrombosis — including the post-thrombotic syndrome that occurs in up to one third of patients<sup>96</sup> — were considered, and if the cost of screening became very low (less than about \$9), screening might be rationalized on economic grounds.<sup>97</sup> Such cost-benefit calculations, however, might be too general to be of use, since the risk of carrying the factor V Leiden mutation varies according to the presence or absence of a family history of thrombosis — presumably because of concomitant genetic or environmental risk factors.<sup>98</sup> Also, denying oral contraceptives to women who test positive for factor V Leiden would leave at least 5 percent of young women without access to the most efficacious form of contraception. Moreover, the implications of a prothrombotic genetic defect in a woman without a history of thrombosis are unclear, and awareness of the presence of the defect has daunting psychosocial, medical, and legal consequences (in terms of insurance, in particular). Finally, the absence of a recognized biochemical or genetic defect does not eliminate the possibility of thrombosis. Even in the absence of one of the defects that are currently known to be relevant, a strong family history of venous thrombosis warrants caution about the use of oral contraceptives, purely on clinical grounds. In the absence of decisive data regarding the risks and benefits of genetic screening before prescribing oral contraceptives, either in the general population or in high-risk families, decisions regarding screening and prescribing should be based on clinical judgment that takes into account each woman's family history and risk factors.<sup>95</sup>

The past five years have yielded key advances in understanding the epidemiology and the hemostatic

mechanisms of the risk of venous thrombosis associated with the use of oral contraceptives. An increased understanding of individual susceptibility to the hemostatic changes induced by oral contraceptives and of markers of the risk of thrombosis should lead to the development of preparations that are even safer.

*We are indebted to the following persons for their previous collaboration and their extensive personal contributions to several of the studies described in this review: Dr. J. Curvers, Dr. G. Nicolaes, Dr. G. Tans, and Mrs. M.C.L.G.D. Thomassen of the Department of Biochemistry, Cardiovascular Research Institute, Maastricht; Professor H.R. Büller, Dr. J.C.M. Meijers, and Dr. M.H. Prins of the Department of Vascular Medicine, Academic Medical Center, Amsterdam; and Professor R.M. Bertina of the Thrombosis and Hemostasis Research Center, Leiden University Medical Center, Leiden—all in the Netherlands.*

## REFERENCES

1. Bonnar J. Coagulation effects of oral contraception. *Am J Obstet Gynecol* 1987;157:1042-8.
2. Stubblefield PG. Cardiovascular effects of oral contraceptives: a review. *Int J Fertil* 1989;34:Suppl:40-9.
3. Kluff C, Lansink M. Effect of oral contraceptives on haemostasis variables. *Thromb Haemost* 1997;78:315-26.
4. Winkler UH. Blood coagulation and oral contraceptives: a critical review. *Contraception* 1998;57:203-9.
5. Petitti DB, Sidney S, Quesenberry CP. Oral contraceptive use and myocardial infarction. *Contraception* 1998;57:143-55.
6. Farley TMM, Meirik O, Collins J. Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks. *Human Reprod Update* 1999;5:721-35.
7. Carter CJ. The natural history and epidemiology of venous thrombosis. *Prog Cardiovasc Dis* 1994;36:423-38.
8. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. *Lancet* 1994;344:1453-7.
9. Stadel BV. Oral contraceptives and cardiovascular disease. *N Engl J Med* 1981;305:612-8.
10. Cardiovascular disease and steroid hormone contraception: report of a WHO scientific group. WHO Tech Rep Ser 1998;877:1-89.
11. Hannaford PC, Owen-Smith V. Using epidemiological data to guide clinical practice: review of studies on cardiovascular disease and use of combined oral contraceptives. *BMJ* 1998;316:984-7.
12. Helmrich SP, Rosenberg L, Kaufman DW, Strom B, Shapiro S. Venous thromboembolism in relation to oral contraceptive use. *Obstet Gynecol* 1987;69:91-5.
13. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. *BMJ* 1986;292:526.
14. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. *Lancet* 1995;346:1575-82.
15. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. *Lancet* 1995;346:1589-93.
16. Lewis MA, Heinemann LAJ, MacRae KD, Bruppacher R, Spitzer WO. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. *Contraception* 1996;54:5-13. [Erratum, *Contraception* 1996;54:121.]
17. Colman RW, Hirsch J, Marder VJ, Salzman EW, eds. Hemostasis and thrombosis: basic principles and clinical practice. 3rd ed. Philadelphia: J.B. Lippincott, 1994:1283-4.
18. Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. *BMJ* 1968;2:199-205.
19. Stolley PD, Tonascia JA, Tockman MS, Sartwell PE, Rutledge AH, Jacobs MP. Thrombosis with low-estrogen oral contraceptives. *Am J Epidemiol* 1975;102:197-208.
20. Realini JP, Encarnacion CE, Chintapalli KN, Rees CR. Oral contraceptives and venous thromboembolism: a case-control study designed to minimize detection bias. *J Am Board Fam Pract* 1997;10:315-21.
21. Bloemenkamp KWM, Rosendaal FR, Büller HR, Helmerhorst FM, Colly LP, Vandenbroucke JP. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. *Arch Intern Med* 1999;159:65-70.
22. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestogens in low dose oestrogen oral contraceptives on venous thromboembolic disease. *Lancet* 1995;346:1582-8.
23. Bloemenkamp KWM, Rosendaal FR, Helmerhorst F, Büller H, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. *Lancet* 1995;346:1593-6.
24. Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. *BMJ* 1996;312:83-8.
25. Farmer RDT, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. *Lancet* 1997;349:83-8.
26. Farmer RDT, Todd JC, MacRae KD, Williams TJ, Lewis MA. Oral contraception was not associated with venous thromboembolic disease in recent study. *BMJ* 1998;316:1090.
27. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. *Arterioscler Thromb Vasc Biol* 1999;19:700-3.
28. Bennet L, Odeberg H. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism. *J Intern Med* 1998;244:27-32.
29. Andersen BS, Olsen J, Nielsen GL, et al. Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism. *Thromb Haemost* 1998;79:23-31.
30. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a case-control study. *Contraception* 1998;57:291-301.
31. Vasilakis C, Jick SS, Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. *Contraception* 1999;59:79-83.
32. Herings RMC, Urquhart J, Leufkens HGM. Venous thromboembolism among new users of different oral contraceptives. *Lancet* 1999;354:127-8. [Erratum, *Lancet* 1999;354:1478.]
33. Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. *Lancet* 1999;354:1610-1.
34. Burnhill MS. The use of a large-scale surveillance system in Planned Parenthood Federation of America clinics to monitor cardiovascular events in users of combination oral contraceptives. *Int J Fertil Womens Med* 1999;44:19-30.
35. Parkin L, Skegg DCG, Wilson M, Herbison GP, Paul C. Oral contraceptives and fatal pulmonary embolism. *Lancet* 2000;355:2133-4.
36. Poulter NR, Farley TMM, Chang CL, Marmot MG, Meirik O. Safety of combined oral contraceptive pills. *Lancet* 1996;347:547.
37. Vandenbroucke JP, Helmerhorst FM, Bloemenkamp KWM, Rosendaal FR. Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. *Am J Obstet Gynecol* 1997;177:887-91.
38. Barbieri RL, Speroff L, Walker AM, McPherson K. Therapeutic controversy: the safety of third-generation oral contraceptives. *J Clin Endocrinol Metab* 1999;84:1822-9.
39. Poulter NR. Risk of fatal pulmonary embolism with oral contraceptives. *Lancet* 2000;355:2088.
40. Skegg DCG. Third generation oral contraceptives. *BMJ* 2000;321:190-1.
41. Spitzer WO. Bias versus causality: interpreting recent evidence of oral contraceptive studies. *Am J Obstet Gynecol* 1998;179:S43-S50.
42. Lewis MA, MacRae KD, Kühl-Habichl D, Bruppacher R, Heinemann LA, Spitzer WO. The differential risk of oral contraceptives: the impact of full exposure history. *Hum Reprod* 1999;14:1493-9.
43. Suissa S, Spitzer WO, Rainville B, Cusson J, Lewis M, Heinemann L. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. *Hum Reprod* 2000;15:817-21.
44. Weiss N. Third-generation oral contraceptives: how risky? *Lancet* 1995;346:1570.
45. McPherson K. Third generation oral contraception and venous thromboembolism. *BMJ* 1996;312:68-9.
46. Walker AM. Newer oral contraceptives and the risk of venous thromboembolism. *Contraception* 1998;57:169-81.
47. O'Brien PA. The third generation oral contraceptive controversy: the



- evidence shows they are less safe than second generation pills. *BMJ* 1999; 319:795-6.
48. Medicines Commission. Combined oral contraceptives containing desogestrel or gestodene and the risk of venous thromboembolism. *Curr Probl Pharmacovigilance* 1999;25:12.
  49. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. *Proc Natl Acad Sci U S A* 1993;90:1004-8.
  50. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. *Nature* 1994;369:64-7.
  51. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. *Lancet* 1995;346:1133-4.
  52. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. *JAMA* 1997;277:1305-7.
  53. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). *Blood* 1995;85:1504-8.
  54. Hellgren M, Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. *Am J Obstet Gynecol* 1995;173:210-3.
  55. Heijboer H, Brandjes DPM, Büller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. *N Engl J Med* 1990;323:1512-6.
  56. Koster T, Rosendaal FR, Briët E, et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). *Blood* 1995;85: 2756-61.
  57. Pabinger I, Kyrle PA, Heisteringer M, Eichinger S, Wittmann E, Lechner K. The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: a prospective cohort study. *Thromb Haemost* 1994;71:441-5.
  58. Simioni P, Sanson BJ, Prandoni P, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. *Thromb Haemost* 1999;81:198-202.
  59. Girolami A, Simioni P, Girolami B, Zanardi S. The role of drugs, particularly oral contraceptives, in triggering thrombosis in congenital defects of coagulation inhibitors: a study of six patients. *Blood Coagul Fibrinolysis* 1991;2:673-8.
  60. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. *Blood* 1996;88:3698-703.
  61. Rosendaal FR, Doggen CJ, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. *Thromb Haemost* 1998;79: 706-8.
  62. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. *Arch Intern Med* 2000;160:49-52.
  63. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. *Lancet* 1995;345:152-5.
  64. Kraaijenhagen RA, in't Anker PS, Koopman MM, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. *Thromb Haemost* 2000;83:5-9.
  65. Jick H, Slone D, Westerholm B, et al. Venous thromboembolic disease and ABO blood type: a cooperative study. *Lancet* 1969;1:539-42.
  66. Bloemenkamp KWM, Helmerhorst FM, Rosendaal FR, Vandenbroucke JP. Venous thrombosis, oral contraceptives and high factor VIII levels. *Thromb Haemost* 1999;82:1024-7.
  67. Robert A, Aillaud MF, Eschwège V, Randrianjohany A, Scarabin Y, Juhan-Vague I. ABO blood group and risk of venous thrombosis in heterozygous carriers of factor V Leiden. *Thromb Haemost* 2000;83:630-1.
  68. Bouma BN, von dem Borne PAK, Meijers JCM. Factor XI and protection of the fibrin clot against lysis — a role for the intrinsic pathway of coagulation in fibrinolysis. *Thromb Haemost* 1998;80:24-7.
  69. Middeldorp S, Meijers JCM, van den Ende AE, et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. *Thromb Haemost* 2000;84:4-8.
  70. Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. *J Biol Chem* 1994;269: 18735-8.
  71. Váradi K, Rosing J, Tans G, Pabinger I, Keil B, Schwarz HP. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor VR506Q mutation. *Thromb Haemost* 1996;76:208-14.
  72. Østerud B, Robertsen R, Åsvang GB, Thijssen F. Resistance to activated protein C is reduced in women using oral contraceptives. *Blood Coagul Fibrinolysis* 1994;5:853-4.
  73. Olivieri O, Friso S, Manzato F, et al. Resistance to activated protein C in healthy women taking oral contraceptives. *Br J Haematol* 1995;91:465-70.
  74. Henskens CMA, Bom VJJ, Seinen AJ, van der Meer J. Sensitivity to activated protein C: influence of oral contraceptives and sex. *Thromb Haemost* 1995;73:402-4.
  75. Lowe GD, Rumley A, Woodward M, Reid E, Rumley J. Activated protein C resistance and the FV:R506Q mutation in a random population sample — associations with cardiovascular risk factors and coagulation variables. *Thromb Haemost* 1999;81:918-24.
  76. Rosing J, Tans G, Nicolaes GAF, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. *Br J Haematol* 1997;97: 233-8.
  77. Vandenbroucke JP, Rosendaal FR. End of line for "third-generation-pill" controversy? *Lancet* 1997;349:1113-4.
  78. Rosing J, Middeldorp S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. *Lancet* 1999;354:2036-40.
  79. Rosing J, Hemker HC, Tans G. Molecular biology and pathophysiology of APC resistance: current insights and clinical implications. *Semin Thromb Hemost* 1998;24:329-35.
  80. de Visser MCH, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. *Blood* 1999;93:1271-6.
  81. Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. *Ann Intern Med* 1999;130:643-50.
  82. Tans G, Curvers J, Middeldorp S, et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. *Thromb Haemost* 2000;84: 15-21.
  83. Meijers JCM, Middeldorp S, Tekelenburg W, et al. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. *Thromb Haemost* 2000;84:9-14.
  84. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. *J Biol Chem* 1995; 270:14477-84.
  85. Von dem Borne PA, Bajzar L, Meijers JC, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. *J Clin Invest* 1997;99:2323-7.
  86. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. *Blood* 2000; 95:2855-9.
  87. Kuhl H, März W, Jung-Hoffmann C, Heidt F, Gross W. Time-dependent alterations in lipid metabolism during treatment with low-dose oral contraceptives. *Am J Obstet Gynecol* 1990;163:363-9.
  88. Farley TMM, Collins J, Schlesselman JJ. Hormonal contraception and risk of cardiovascular disease: an international perspective. *Contraception* 1998;57:211-30.
  89. Deaths with third generation oral contraceptives. Wellington, New Zealand: New Zealand Department of Health, December 1998. (See <http://www.medsafe.govt.nz/Profes/PUarticles.htm>.) (See NAPS document no. 05591 for 3 pages, c/o Microfiche Publications, 248 Hempstead Tpke., West Hempstead, NY 11552.)
  90. Heinemann LAJ, Lewis MA, Thorogood M, Spitzer WO, Guggenmoos-Holzmann I, Bruppacher R. Case-control study of oral contraceptives and risk of thromboembolic stroke: results from International Study on Oral Contraceptives and Health of Young Women. *BMJ* 1997;315: 1502-4.
  91. Dunn N, Thorogood M, Faragher B, et al. Oral contraceptives and myocardial infarction: results of the MICA case-control study. *BMJ* 1999; 318:1579-83.
  92. Badaracco MA, Vessey MP. Recurrence of venous thromboembolic disease and use of oral contraceptives. *BMJ* 1974;1:215-7.
  93. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives: results of an international, multicenter, case-control study. *Contraception* 1998;57:315-24.
  94. Campbell B. Thrombosis, phlebitis and varicose veins. *BMJ* 1996;312: 198-9.
  95. Vandenbroucke JP, van der Meer FJM, Helmerhorst FM, Rosendaal

FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women? *BMJ* 1996;313:1127-30.

**96.** Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. *Ann Intern Med* 1996;125:1-7.

**97.** Szucs T, Osterkorn D, Schramm W. Gesundheitsökonomische Evalu-

ation des Screenings auf APC-Resistenz (Mutation Leiden) bei Neuanwenderinnen von Ovulationshemmern. *Med Klin* 1996;91:317-9.

**98.** Lensen RPM, Rosendaal FR, Koster T, et al. Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients. *Blood* 1996;88:4205-8.

Copyright © 2001 Massachusetts Medical Society.